REFERENCES
- DiFrancesco R, Holland DT, Schiffhauer JE, Robbins BL, Tooley KM, Morse GD. A quality assurance program for AIDS clinical trials group pharmacology studies. Qua! Assur J. 2005;9:23–30.
- StatXact 7 PROCs for SAS Users. A software package for exact nonparametric inference. Cambridge, MA: Cytel Inc; 2005.
- Blyth CR, Still HA. Binomial confidence intervals. J Am Stat Assoc. 1983;78:108–116.
- Fletcher CV, Acosta EP, Cheng H, et al., for the ACTG 884 Protocol Team. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 2000;14(16): 2495–2501.
- Fletcher CV, Jiang H, Brundage RC, et al. Sex-based dif-ferences in saquinavir pharmacology and virologic re-sponse in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004;189:1176–1184.
- DiCenzo R, Forrest A, Squires KE, et al., and the Adult AIDS Clinical Trials Group Protocol 368/886 Study Team. Indinavir, efavirenz, and abacavir pharmacokinetics in hu-man immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47(6):1929–1935.
- Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391–2400.
- Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinua-tion: an adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42:401–407.
- Jian-Feng L, Blaschke TF, Flexner C, Rosenkranz SL, Sheiner LB. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. Drug Metabol Disposition. 2002:30;1455–1461.